Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study

  • Authors:
    • Matteo Santoni
    • Alessandro Paccapelo
    • Luciano Burattini
    • Maristella Bianconi
    • Massimo Cardinali
    • Letizia Fabbietti
    • Roberto Trignani
    • Franco Rychlicki
    • Stefano Cascinu
  • View Affiliations

  • Published online on: July 5, 2012     https://doi.org/10.3892/ol.2012.788
  • Pages: 799-801
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

O6-alkylguanine‑DNA alkyltransferase (AGAT), involved in temozolomide‑induced DNA damage repair, plays a key role in the efficacy of temozolomide. AGAT activity may be reduced by protracted temozolomide doses. On the basis of the preclinical findings, we treated patients with a histologically‑proven diagnosis of glioblastoma (GBM) following adjuvant temozolomide failure with a low protracted dose of temozolomide (130 mg/m2/day, days 1‑7 and 15‑21, every 4 weeks). The primary endpoint of the study was 6‑month progression‑free survival (PFS‑6 m). The secondary endpoints were overall survival (OS) from the start of temozolomide alternative schedule and toxicity. Enrolment was ceased at 27 patients due to the lack of effectiveness of this regimen. Results indicate that our schedule is well‑tolerated, but ineffective in patients with GBM and further strategies are required to improve the outcome of these patients.
View References

Related Articles

Journal Cover

October 2012
Volume 4 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Santoni M, Paccapelo A, Burattini L, Bianconi M, Cardinali M, Fabbietti L, Trignani R, Rychlicki F and Cascinu S: Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncol Lett 4: 799-801, 2012
APA
Santoni, M., Paccapelo, A., Burattini, L., Bianconi, M., Cardinali, M., Fabbietti, L. ... Cascinu, S. (2012). Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncology Letters, 4, 799-801. https://doi.org/10.3892/ol.2012.788
MLA
Santoni, M., Paccapelo, A., Burattini, L., Bianconi, M., Cardinali, M., Fabbietti, L., Trignani, R., Rychlicki, F., Cascinu, S."Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study". Oncology Letters 4.4 (2012): 799-801.
Chicago
Santoni, M., Paccapelo, A., Burattini, L., Bianconi, M., Cardinali, M., Fabbietti, L., Trignani, R., Rychlicki, F., Cascinu, S."Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study". Oncology Letters 4, no. 4 (2012): 799-801. https://doi.org/10.3892/ol.2012.788